羟乙基淀粉联合阿托伐他汀治疗分水岭脑梗死患者的临床效果
|
摘要
目的探讨羟乙基淀粉联合阿托伐他汀治疗分水岭脑梗死患者的临床效果。方法选取凌源市中心医院于2016年10月至2018年12月收治的100例分水岭脑梗死患者作为研究对象,采用随机数字表法将其分为对照组和试验组,每组50例。对照组患者在常规治疗的基础上加用阿托伐他汀治疗,试验组患者在对照组患者基础上加用羟乙基淀粉治疗,比较两组的临床效果。结果试验组的治疗有效率为94.00%,显著高于对照组的78.00%,差异有统计学意义(P<0.05);治疗后,试验组患者的美国国立卫生研究院卒中量表(NIHSS)评分显著低于对照组患者,差异有统计学意义(P<0.05);治疗28 d后,两组患者的纤维蛋白原(FIB)、血浆黏度(PSV)、全血黏度(WBV)高切和低切均有所降低,而脑血流量(CBF)有所升高,且试验组患者的变化幅度均大于对照组,差异有统计学意义(均P<0.05)。结论羟乙基淀粉联合阿托伐他汀治疗分水岭脑梗死临床效果显著,可改善患者的血流动力学,还有助于改善患者神经功能缺损情况。
Objective To explore the clinical efficacy of hydroxyethyl starch combined with atorvastatin in the treatment of patients with watershed cerebral infarction. Methods A total of 100 patients with watershed cerebral infarction admitted to the Lingyuan Central Hospital from October 2016 to December 2018 were selected as the research objects, and they were randomly divided into control group and experimental group(50 cases in each group). Patients in the control group were treated with atorvastatin on the basis of routine treatment, while patients in the experimental group were treated with hydroxyethyl starch on the treatment basis of the control group. The clinical efficacy of the 2 groups were compared. Results The total clinical effective rate of the experimental group was94.00%, significantly higher than that of the control group(78.00%), with statistical significance(P<0.05); after the treatment, the national institutes of health stroke scale(NIHSS) score of the experimental group was significantly lower than that of the control group,with statistical significance(P<0.05); after 28 days of the treatment, fibrinogen(FIB), pressure of vein(PV) and whole blood viscosity(WBV) of both high shear rate and low shear rate in the 2 groups were decreased, while cerebral blood flow(CBF) was increased, and the change range of the experimental group was greater than that of the control group, with statistical significance(P<0.05).Conclusion Hydroxyethyl starch combined with atorvastatin in the treatment of watershed cerebral infarction patients has significant clinical efficacy, which can improve the hemodynamics of patients, and help to improve the neurological deficits of patients.
Objective To explore the clinical efficacy of hydroxyethyl starch combined with atorvastatin in the treatment of patients with watershed cerebral infarction. Methods A total of 100 patients with watershed cerebral infarction admitted to the Lingyuan Central Hospital from October 2016 to December 2018 were selected as the research objects, and they were randomly divided into control group and experimental group(50 cases in each group). Patients in the control group were treated with atorvastatin on the basis of routine treatment, while patients in the experimental group were treated with hydroxyethyl starch on the treatment basis of the control group. The clinical efficacy of the 2 groups were compared. Results The total clinical effective rate of the experimental group was94.00%, significantly higher than that of the control group(78.00%), with statistical significance(P<0.05); after the treatment, the national institutes of health stroke scale(NIHSS) score of the experimental group was significantly lower than that of the control group,with statistical significance(P<0.05); after 28 days of the treatment, fibrinogen(FIB), pressure of vein(PV) and whole blood viscosity(WBV) of both high shear rate and low shear rate in the 2 groups were decreased, while cerebral blood flow(CBF) was increased, and the change range of the experimental group was greater than that of the control group, with statistical significance(P<0.05).Conclusion Hydroxyethyl starch combined with atorvastatin in the treatment of watershed cerebral infarction patients has significant clinical efficacy, which can improve the hemodynamics of patients, and help to improve the neurological deficits of patients.
引文
[1]齐智慧.羟乙基淀粉联合阿托伐他汀治疗分水岭脑梗死的效果[J].河南医学研究, 2018, 27(24):4484-4485.
[2]杨凡,魏书艳,王佩,等.羟乙基淀粉联合阿托伐他汀治疗分水岭脑梗死的临床疗效[J].医学综述, 2018, 24(10):2073-2076.
[3]胡迪.阿托伐他汀钙联合羟乙基淀粉针治疗分水岭脑梗死的临床效果[J].泰山医学院学报, 2017, 38(3):341-342.
[4]赵斌,刘娜娜.阿托伐他汀钙联合羟乙基淀粉注射液治疗分水岭脑梗死的临床效果研究[J].中国医学前沿杂志(电子版), 2015,7(6):159-161.
[5]刘婉婷,许治强.羟乙基淀粉联合阿托伐他汀改善分水岭脑梗死患者神经功能缺损程度的作用[J].中国实用神经疾病杂志,2014,(23):108-109, 110.
[6]崔丽娟,范爱华,邓小勇.阿托伐他汀钙联合羟乙基淀粉针治疗分水岭脑梗死临床疗效研究[J].临床医学工程,2013,20(5):589-590.
[7]李阳.阿托伐他汀钙联合羟乙基淀粉治疗急性脑分水岭梗死的疗效[J].中外医学研究, 2013,11(25):22-22.
[8]蔡平太.瑞舒伐他汀联合羟乙基淀粉针治疗分水岭脑梗死的疗效观察[J].中国实用神经疾病杂志, 2015, 18(17):107-108.
[9]姜玉龙,吴卫文,武刚,等.羟乙基淀粉扩容治疗大脑中动脉狭窄致内分水岭脑梗死效果观察[J].山东医药,2015,55(37):86-87.
[10]刘小双.羟乙基淀粉联合前列地尔治疗急性脑分水岭梗死的疗效[J].中国实用医刊, 2016, 43(2):111-112.
[11]肖彧,彭慕立,苏赤,等.羟乙基淀粉40氯化钠注射液联合低分子肝素治疗急性分水岭脑梗死的临床研究[J].中国医学创新,2018, 15(16):31-33.
[2]杨凡,魏书艳,王佩,等.羟乙基淀粉联合阿托伐他汀治疗分水岭脑梗死的临床疗效[J].医学综述, 2018, 24(10):2073-2076.
[3]胡迪.阿托伐他汀钙联合羟乙基淀粉针治疗分水岭脑梗死的临床效果[J].泰山医学院学报, 2017, 38(3):341-342.
[4]赵斌,刘娜娜.阿托伐他汀钙联合羟乙基淀粉注射液治疗分水岭脑梗死的临床效果研究[J].中国医学前沿杂志(电子版), 2015,7(6):159-161.
[5]刘婉婷,许治强.羟乙基淀粉联合阿托伐他汀改善分水岭脑梗死患者神经功能缺损程度的作用[J].中国实用神经疾病杂志,2014,(23):108-109, 110.
[6]崔丽娟,范爱华,邓小勇.阿托伐他汀钙联合羟乙基淀粉针治疗分水岭脑梗死临床疗效研究[J].临床医学工程,2013,20(5):589-590.
[7]李阳.阿托伐他汀钙联合羟乙基淀粉治疗急性脑分水岭梗死的疗效[J].中外医学研究, 2013,11(25):22-22.
[8]蔡平太.瑞舒伐他汀联合羟乙基淀粉针治疗分水岭脑梗死的疗效观察[J].中国实用神经疾病杂志, 2015, 18(17):107-108.
[9]姜玉龙,吴卫文,武刚,等.羟乙基淀粉扩容治疗大脑中动脉狭窄致内分水岭脑梗死效果观察[J].山东医药,2015,55(37):86-87.
[10]刘小双.羟乙基淀粉联合前列地尔治疗急性脑分水岭梗死的疗效[J].中国实用医刊, 2016, 43(2):111-112.
[11]肖彧,彭慕立,苏赤,等.羟乙基淀粉40氯化钠注射液联合低分子肝素治疗急性分水岭脑梗死的临床研究[J].中国医学创新,2018, 15(16):31-33.